CA2481462A1 - Heteroclitic analogs and related methods - Google Patents

Heteroclitic analogs and related methods Download PDF

Info

Publication number
CA2481462A1
CA2481462A1 CA002481462A CA2481462A CA2481462A1 CA 2481462 A1 CA2481462 A1 CA 2481462A1 CA 002481462 A CA002481462 A CA 002481462A CA 2481462 A CA2481462 A CA 2481462A CA 2481462 A1 CA2481462 A1 CA 2481462A1
Authority
CA
Canada
Prior art keywords
epitope
peptide
seq
analog
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002481462A
Other languages
English (en)
French (fr)
Inventor
Glenn Ishioka
John Fikes
Shabnam Tangri
Alessandro Sette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/116,118 external-priority patent/US8741576B2/en
Application filed by Individual filed Critical Individual
Publication of CA2481462A1 publication Critical patent/CA2481462A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002481462A 2002-04-05 2003-04-07 Heteroclitic analogs and related methods Abandoned CA2481462A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/116,118 US8741576B2 (en) 1999-11-18 2002-04-05 Heteroclitic analogs and related methods
US10/116,118 2002-04-05
US41347102P 2002-09-26 2002-09-26
US60/413,471 2002-09-26
PCT/US2003/010571 WO2003087126A2 (en) 2002-04-05 2003-04-07 Heteroclitic analogs and related methods

Publications (1)

Publication Number Publication Date
CA2481462A1 true CA2481462A1 (en) 2003-10-23

Family

ID=29253934

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002481462A Abandoned CA2481462A1 (en) 2002-04-05 2003-04-07 Heteroclitic analogs and related methods

Country Status (6)

Country Link
US (1) US20060018915A1 (https=)
EP (1) EP1495322A4 (https=)
JP (1) JP2005522212A (https=)
AU (1) AU2003221831A1 (https=)
CA (1) CA2481462A1 (https=)
WO (1) WO2003087126A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720118D0 (en) * 2007-10-15 2007-11-28 Achour Adnane Modified mhc class 1 binding peptides
BRPI0817682A2 (pt) 2007-10-16 2015-04-07 Peptimmune Inc Métodos para projetar e preparar vacinas compreendendo composições de polímero de sequência direcionada via a expansão direta de epítopos
US8711176B2 (en) 2008-05-22 2014-04-29 Yahoo! Inc. Virtual billboards
US20090289955A1 (en) * 2008-05-22 2009-11-26 Yahoo! Inc. Reality overlay device
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
PT2413956T (pt) * 2009-04-02 2016-12-30 Vaxon Biotech Identificação, optimização e utilização de epitopos crípticos hla-a24 para imunoterapia
WO2011083493A1 (en) * 2010-01-08 2011-07-14 National Institute Of Immunology Human chorionic gonadotropin (hcg) based vaccine for prevention and treatment of cancer
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
CN108503689B (zh) * 2017-07-10 2019-12-31 昆明医科大学第一附属医院 一种抗血小板聚集的多肽km6
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
JP2001504799A (ja) * 1996-03-11 2001-04-10 エピミューン インコーポレイテッド Ｈｌａ分子への結合アフィニティーが増加したペプチド
EP1064022A4 (en) * 1998-03-13 2004-09-29 Epimmune Inc HLA BINDING PROTEINS AND THEIR USE
US6632435B1 (en) * 1999-10-20 2003-10-14 City Of Hope CTL epitope analogs
AU1661201A (en) * 1999-11-18 2001-05-30 Epimmune, Inc. Heteroclitic analogs and related methods
WO2002020616A1 (en) * 2000-09-01 2002-03-14 Epimmune Inc. Hla-a2.1 binding peptides and their uses

Also Published As

Publication number Publication date
EP1495322A4 (en) 2006-09-06
WO2003087126A3 (en) 2004-10-28
US20060018915A1 (en) 2006-01-26
AU2003221831A1 (en) 2003-10-27
JP2005522212A (ja) 2005-07-28
EP1495322A2 (en) 2005-01-12
WO2003087126A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
EP1230268B1 (en) Heteroclitic analogs of class i epitopes
CA2522812C (en) Hla-a2 tumor associated antigen peptides and compositions
US20060094649A1 (en) Hla-a1,-a2,-a3,-a24,-b7, and-b44 tumor associated antigen peptides and compositions
US20110318408A1 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
US20070020327A1 (en) Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
EP1568373A2 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
WO2001045728A2 (en) Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
EP1242049A1 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
CA2481462A1 (en) Heteroclitic analogs and related methods
CA2392764A1 (en) Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
CA2393339A1 (en) Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
US20040048790A1 (en) Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
EP1903056A2 (en) HLA-A1, -A2 -A3, -A24, -B7, and -B44 tumor associated antigen peptides and compositions

Legal Events

Date Code Title Description
FZDE Discontinued